
North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Health Information Designs, Inc.

Fall 2010

Welcome to the Fall 2010 edition of the “North Dakota Medicaid Pharmacy Program Quarterly News,” a pharmacy newsletter presented by the North Dakota Department of Human Services and published by Health Information Designs, Inc. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Human Services has contracted with Health Information Designs, Inc. (HID) to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit www.hidndmedicaid.com, or call HID at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup. This allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

The Fall 2010 newsletter provides information on the drug classes that have been recently added to the list of medications requiring prior authorization. Name-brand narcotics were placed on the list December 1, 2010. Instructions on how to request prior authorization for these medications are also provided.

The North Dakota Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, or to make comments, please contact Health Information Designs, Inc. at (334) 502-3262, call toll free at 1-800-225-6998, or e-mail us at info@hidinc.com.



Helpful Numbers

PA Help Desk 866-773-0695
To fax PAs 866-254-0761
To report adverse reactions 800-FDA-1088

Inside this issue:	Page
Welcome	1
Helpful Numbers	1
Name-Brand Narcotics PA	2
Prior Authorization Update	3
Health Information Designs, Inc.	4

Visit HID's North Dakota Department of Human Services Prior Authorization Webpage, www.hidndmedicaid.com.

Brand Name Narcotics Prior Authorization

The 2003 Legislative Assembly passed House Bill 1430, creating a Drug Utilization Review (DUR) Board to advise the Department of Human Services in developing a Prior Authorization (PA) process to help assure that beneficiaries receive appropriate medications in the most cost-effective manner, thus conserving state expenditures for drugs whenever possible.

The DUR Board, consisting of six physicians, six pharmacists, two non-voting members of the Department, two non-voting members from the pharmaceutical industry, and one community representative, has reviewed and supports the Department's plan to implement the PA process for Name Brand Narcotics. This notice provides important details on how physicians and patients will continue to access Medicaid pharmaceutical benefits under the PA process for these medications.

Directions for Physicians

As the prescribing physician, the next time you prescribe a name brand narcotic for your patient not currently stable on therapy, you must request a PA. Patients receiving a new prescription for a brand name narcotic must first try a 30-day trial of a generic narcotic. Necessary forms and criteria are located on the HID website at www.hidndmedicaid.com, or call HID at (866) 773-0695 to have this information faxed. If you do not request a PA, the Department will deny the claim at the pharmacy. You will then be contacted by the pharmacy and asked to change the prescription or to request prior authorization for the product specified on the original prescription.

Current Name-Brand Narcotic Utilization			
12/28/09 - 12/27/10			
Label Name	Rx Num	Total Reimb Amt	Avg Cost per Script
KADIAN ER 100 MG CAPSULE	4	\$3,832.80	\$958.20
OXYCONTIN 80 MG TABLET	85	\$68,843.04	\$809.92
KADIAN ER 80 MG CAPSULE	3	\$2,022.51	\$674.17
EMBEDA 80-3.2 MG CAPSULE	6	\$3,555.67	\$592.61
KADIAN ER 60 MG CAPSULE	31	\$16,893.14	\$544.94
OXYCONTIN 60 MG TABLET	54	\$27,554.91	\$510.28
KADIAN ER 50 MG CAPSULE	19	\$7,976.59	\$419.82
AVINZA 120 MG CAPSULE	12	\$4,966.46	\$413.87
OXYCONTIN 40 MG TABLET	267	\$104,759.31	\$392.36
EMBEDA 60-2.4 MG CAPSULE	22	\$8,549.33	\$388.61
AVINZA 90 MG CAPSULE	24	\$8,424.32	\$351.01
EMBEDA 50-2 MG CAPSULE	18	\$6,277.18	\$348.73
OPANA ER 20 MG TABLET	15	\$4,974.90	\$331.66
OPANA 10 MG TABLET	2	\$645.12	\$322.56
OPANA 5 MG TABLET	27	\$7,658.65	\$283.65
OXYCONTIN 30 MG TABLET	97	\$24,762.15	\$255.28
EMBEDA 100-4 MG CAPSULE	11	\$2,673.20	\$243.02
KADIAN ER 30 MG CAPSULE	55	\$12,330.21	\$224.19

Current Name-Brand Narcotic Utilization (cont'd)			
12/28/09 - 12/27/10			
Label Name	Rx Num	Total Reimb Amt	Avg Cost per Script
KADIAN ER 20 MG CAPSULE	22	\$4,624.12	\$210.19
OXYCONTIN 20 MG TABLET	268	\$56,011.82	\$209.00
AVINZA 60 MG CAPSULE	16	\$3,328.60	\$208.04
NUCYNTA 100 MG TABLET	12	\$2,262.54	\$188.55
EMBEDA 30-1.2 MG CAPSULE	58	\$10,684.44	\$184.21
OPANA ER 10 MG TABLET	13	\$2,366.41	\$182.03
EMBEDA 20-0.8 MG CAPSULE	48	\$8,676.36	\$180.76
MS CONTIN 15 MG TABLET	2	\$328.70	\$164.35
OPANA ER 7.5 MG TABLET	2	\$327.58	\$163.79
OXYCONTIN 15 MG TABLET	19	\$2,580.90	\$135.84
AVINZA 30 MG CAPSULE	35	\$4,246.16	\$121.32
OPANA ER 5 MG TABLET	2	\$225.36	\$112.68
OXYCONTIN 10 MG TABLET	216	\$22,594.12	\$104.60
NUCYNTA 50 MG TABLET	43	\$3,850.58	\$89.55
NUCYNTA 75 MG TABLET	3	\$244.76	\$81.59
CAPITAL WITH CODEINE SUSP	202	\$13,963.34	\$69.13
KADIAN ER 10 MG CAPSULE	2	\$95.20	\$47.60
ORAMORPH SR 15 MG TABLET	2	\$22.70	\$11.35
Totals	1717	\$453,133.18	
Total Opiate Agonist Spend 12/28/09 - 12/27/10 \$1,519,606.70			

Prior Authorization Updates

Drug or Class	Criteria for Coverage
Topical Anesthetic Agents	Medical procedure on PA form
Name Brand Narcotics	30 day trial of a generic narcotic
Suboxone/Subutex	Documented opioid dependence, SAMHSA ID, not taking opioids, tramadol or carisoprodol concurrently.
Ampyra	Neurologist/physiatrist involved in therapy, diagnosis of MS, no history of seizures, CrCl greater than 50mL/min.
Ultram ER, Ryzolt, Rybix	Documented trial of generic immediate release tramadol.



Health Information Designs, Inc. (HID) is the most experienced and qualified provider of drug utilization review and pharmacy support services in the country. We specialize in helping our clients promote clinically appropriate and cost-effective prescribing, dispensing, and utilization of prescription drugs.

For 33 years, HID has worked to improve the quality and cost effectiveness of health care through clinically rational use of prescription medication. Our clients include public and private healthcare plans throughout the U.S. with a combined total of over 14 million covered lives.

Health Information Designs, Inc. was founded in 1976 and is incorporated as a C Corporation in the State of Delaware. HID's initial mission was to market drug utilization review (DUR) services nationally and since its founding, has provided DUR services for clients in approximately two-thirds of the United States. HID is headquartered in Auburn, Alabama, with regional offices in Arkansas, Maryland, and Mississippi.

HEALTH
INFORMATION DESIGNS

391 Industry Drive
Auburn, AL 36832
Tel: 800-748-0130
Fax: 800-748-0116

PRST STD
U.S. Postage